Gliosarcoma in patients under 20 years of age. A clinicopathologic study of 11 cases and detailed review of the literature by Din, Nasir Ud et al.
eCommons@AKU 
Department of Pathology and Laboratory 
Medicine Medical College, Pakistan 
2-26-2021 
Gliosarcoma in patients under 20 years of age. A 
clinicopathologic study of 11 cases and detailed review of the 
literature 
Nasir Ud Din 
Hira Ishtiaq 
Shabina Rahim 
Jamshid Abdul Ghafar 
Zubair Ahmad 
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol 
 Part of the Neurology Commons, Neurosurgery Commons, Pathological Conditions, Signs and 
Symptoms Commons, Pathology Commons, and the Pediatrics Commons 
RESEARCH ARTICLE Open Access
Gliosarcoma in patients under 20 years of
age. A clinicopathologic study of 11 cases
and detailed review of the literature
Nasir Ud Din1, Hira Ishtiaq1, Shabina Rahim1, Jamshid Abdul-Ghafar2* and Zubair Ahmad1
Abstract
Background: Gliosarcoma is a rare variant of IDH- wild type glioblastoma with both glial and mesenchymal
differentiation. It accounts for approximately 2% of glioblastomas and has a poor prognosis similar to that of classic
glioblastoma. It is seen mostly between 40 and 60 years of age with a mean age over 50 years. Pediatric
gliosarcoma is even rarer than gliosarcoma in adults. We describe the clinicopathological features of gliosarcoma in
patients under 20 years of age and determine whether there are significant differences from gliosarcoma in adults.
We also present detailed review of published literature on pediatric gliosarcoma.
Methods: Slides of gliosarcomas in patients under 20 years of age were reviewed. Clinicopathological features were
noted in detail and follow up was obtained.
Results: Eleven cases of gliosarcoma were reported in patients under 20 years of age. Ages ranged from three to
19 years (mean age 13 years). Frontal, parietal and temporal lobes were the commonest locations. Mean and
median tumor size was six and five cm respectively. All 11 cases demonstrated the classic biphasic pattern. In 10
cases, glial component was astrocytic and was highlighted on GFAP. Sarcomatous component in most cases
resembled fibrosarcoma and was high grade in 72.7%. Glial areas were reticulin poor while sarcomatous areas were
reticulin rich. In over 45% cases, bizarre tumor giant cells were seen in the sarcomatous areas. In 1 case,
sarcomatous areas showed extensive bone and cartilage formation. Other histologic features included hyalinized
blood vessels, hemorrhage, infarction, gemistocytic cells, rhabdoid cells etc. Follow up was available in nine
patients, five received chemoradiation post resection while three received radiotherapy only. Prognosis was dismal
and eight patients died within one to 14 months following resection.
Conclusions: Gliosarcomas in patients under 20 comprised 13% of all gliosarcomas reported during the study
period. Frequency and mean age were higher compared to other published reports. Pathological features were
similar to those described in literature. Clinicopathological features and prognosis of pediatric gliosarcomas were
similar to adult gliosarcomas.
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Introduction
Gliosarcoma, World Health Organization (WHO) grade
IV is a rare variant of Isocitrate Dehydrogenase (IDH)-
wild type glioblastoma with both glial and mesenchymal
differentiation and accounts for approximately 2% of
glioblastomas. It has a poor prognosis similar to that of
classic glioblastoma. It is seen mostly between 40 and
60 years of age with a mean age above 50 years, is more
common in males and occurs mainly in the cerebral
hemispheres with the temporal and frontal lobes being
the commonest locations. It is characterized histologi-
cally by a biphasic pattern composed of alternating glial
and mesenchymal (sarcomatous) areas. Both glial and
mesenchymal components represent monoclonal prolif-
erations. The clinical profile, imaging, spread and
macroscopic appearance of this variant are similar to
classic glioblastoma. It is often superficial and decep-
tively circumscribed. Pediatric gliosarcoma is even rarer
than gliosarcoma in adults [1, 2].
Histologically, the glial component is usually astro-
cytic (like the classic astrocytic glioblastoma) with an-
aplastic features. Sarcomatous component usually
manifests as a spindle cell sarcoma with nuclear aty-
pia, mitoses and necrosis. The glial areas are reticulin
poor while the sarcomatous areas are reticulin rich
(highlighted on reticulin stain). On immunohisto-
chemical (IHC) staining, glial areas express glial fibril-
lary acidic protein (GFAP) while the sarcomatous
areas are negative [1].
Pediatric gliosarcoma, as stated above, is even rarer.
To the best of our knowledge, 45 cases have been re-
ported in literature [3–36].
Herein, we present a series of 11 cases of gliosarcoma
reported in patients under 20 years of age. The aim of
this study is to describe the clinicopathological features
of gliosarcoma reported in patients under 20 and to de-
termine whether there are significant differences from
gliosarcomas occurring in adults. We also present a de-
tailed review of published literature on these extremely
rare tumors.
Methods
The Surgical Pathology files of the Section of Histopath-
ology, Department of Pathology and Laboratory
Medicine, Aga Khan University Hospital, were searched
for gliosarcomas reported between July 1, 2011 and June
30, 2019. Cases reported in patients under 20 years were
identified. Slides of these cases were retrieved and were
reviewed by the senior authors. The diagnosis was con-
firmed. Clinical and pathological features were described
in detail. Follow up was obtained through verbal tele-
phonic communication with the parents. Ethical exemp-
tion was obtained from the Aga Khan University Ethical
Review Committee (ERC). All procedures performed on
patient tumor samples in this study were in accordance
with the ethical standards of the Institutional ERC and
with the 1964 Helsinki declaration and its later amend-
ments or comparable ethical standards. Detailed review
of published literature was conducted by the authors.
We systematically searched PubMed, Google Scholar
and Web of Science detailed for articles on pediatric
gliosarcoma with restriction of ‘original article’ and ‘case
reports’. We only included articles with English ab-
stracts. We searched using the Medical Subject Heading
(MESH) terms and key words ‘pediatric gliosarcoma’. A
total of 34 articles were included. Review articles were
not included. We collected demographics, clinicopatho-
logical and follow up information. All selected articles
were assessed for eligibility. All were found to be eligible.
No duplicates were found. All 34 were included in quali-
tative synthesis.
Results
During the study period (2011–2019), 84 cases of
gliosarcoma were reported. Of these, 11 (31.1%) were re-
ported in patients younger than 20 years of age. Clinico-
pathological features are summarized in Table 1. Of
these 11 patients, 6(54.5%) were males and 5(45.5%)
were females. Ages of patients ranged from 3 to 19 years
with mean and median age of 13 and 16 years respect-
ively. Four patients (36.4%) were under 10 years of age.
Of the 11 cases, 3(27.3%) were located in the frontal and
2(18.2%) in the parietal lobes; one case each was
temporal, frontotemporal, temporo-parietal, parieto-
occipital, occipital and sellar in location (Fig. 1a-d). All
cases were received as multiple pieces of tumor tissue
ranging from 1.5 cm to 12 cm in aggregate with mean
and median size of 6 cm and 5 cm respectively. Gross
total resection was apparently not achieved in any of the
cases. On histologic examination, all 11 cases demon-
strated the classic biphasic pattern (Fig. 2a). Glial com-
ponent was astrocytic in 10 cases (90.9%) and
oligodendroglial in 1 case (Fig. 2b). Glial component was
highlighted in all 11 cases on IHC stain for GFAP (Fig.
2c). Sarcomatous component in most cases manifested
as a spindle cell sarcoma resembling fibrosarcoma (Fig.
2d). Sarcomatous component was high grade in 8
(72.7%) cases and low grade in 3 (27.3%) cases. Sarcoma-
tous areas were highlighted on IHC stain for vimentin
(Fig. 3a). Glial areas were reticulin poor (Fig. 3b) while
sarcomatous areas were reticulin rich (Fig. 3c). In 5
(45.5%) cases, sarcomatous areas showed considerable
atypia in the form of bizarre tumor giant cells (Fig. 3d).
In 1 case, the sarcomatous component showed add-
itional lines of mesenchymal differentiation in the form
of extensive bone and cartilage formation (Fig. 4a).
Prominent hyalinized blood vessels (Fig. 4b) were seen
in 3 (27.3%) cases while hemorrhage and infarction were
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noted in 2 cases. Gemistocytic (Fig. 4c) and rhabdoid
(Fig. 4d) cells were seen in 1 and 2 cases respectively.
Follow up was available in 9 cases. Of these 9 patients,
5 received both chemotherapy and radiotherapy post-
surgery while 3 received radiotherapy only. One pa-
tient did not receive either chemotherapy or radio-
therapy. Of these 9 patients, 8 died within 1 month to
14 months following surgery while the 9th patient was
alive 6 months post-surgery.
Discussion
Pediatric gliosarcomas are even rarer than adult glio-
sarcomas. Clinical and morphological features are
similar to adult gliosarcomas. However, they may
mimic more common tumors on radiological and
histological examination. The clinicopathological fea-
tures and differential diagnostic consideration are
discussed. Published literature is reviewed.
Table 1 Clinicopathological features of pediatric gliosarcomas (n = 11)
S.Num Age/Sex Site Tumor size in biopsy (cm) Chemotherapy Radiotherapy Survival following surgery
1 12/F Right cerebral cortex 2 x 2 x 1.5 Received Received Alive 6 months following resection
2 14/F Right parietal lobe NK Received Received DOD 4months following resection
3 15/F Sellar & suprasellar 6.4 × 6.1 × 4 Not received Received DOD 1month following resection
4 18/M Left parieto-occipital lobe 3 x 2 x 1.5 Received Received DOD 14months after resection
5 3/M Fronto-parietal lobe 10 x 7 x 5 Not received Received DOD 6months after resection
6 16/F Left frontal lobe 5 × 1.9 × 1.5 Received Received DOD 3months after resection
7 8/F Left temporal lobe 5 x 4 x 3 Not received Received DOD 1month following resection
8 19/M Left parietal lobe 7.3 × 5.5 × 2 Not received Not received DOD 8months following resection
9 5/M Right frontal lobe 12 x 11 x 3 Received Received DOD 3months following resection
10 10/M Frontal lobe 1.5 × 1.5 × 0.3 NK NK Lost to follow up
11 15/M Left parietal lobe 5 × 3.5 × 2 cm NK NK Lost to follow up
DOD died of disease; NK not known
Fig. 1 a T2WI Axial Image: A well-defined rounded T2WI heterogenous signal intensity mass seen in right parietal lobe with significant
perilesional edema. b T2WI Sagittal Image: A well-defined rounded T2WI heterogenous signal intensity mass seen in right parietal lobe with
significant perilesional edema c T1 Axial post-contrast: Avid post contrast enhancing mass with few central hypointensities identified in right
posterior parietal lobe and surrounding perilesional edema. d T1 coronal post contrast image: Avid post contrast enhancing mass with few
central hypointensities identified in right posterior parietal lobe and shows surrounding perilesional edema
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On radiological examination, the relative discreteness
of these tumors may mimic meningioma [37, 38]. Simi-
larly, on gross examination, the appearance of a firm
well-circumscribed mass with attachment to dura may
be mistaken with a meningioma or metastases, although
such confusion is more likely in adults rather than in the
pediatric age group [1]. On histological examination, the
diagnosis in typical cases even in pediatric age group is
straightforward when the classic biphasic pattern is well
developed. However, the sarcomatous areas in both
adult and pediatric gliosarcoma can resemble fibrosar-
coma. Some cases may show other types of mesenchy-
mal differentiation such as bone and cartilage formation
(resembling osteo-or chondrosarcoma), smooth and stri-
ated muscle differentiation (resembling leiomyosarcoma
and rhabdomyosarcoma), lipomatous differentiation (re-
sembling liposarcoma) and primitive neural differenti-
ation. Variable mesenchymal differentiation was seen in
Fig. 2 a Classic biphasic appearance of gliosarcoma. The mesenchymal elements at top are sharply demarcated from glial component at bottom.
b Oligodendroglioma as glial component was seen in one case. c. GFAP expression in the glial component. d. Mesenchymal component
appeared as fibrosarcoma in most cases
Fig. 3 a. Vimentin positivity in mesenchymal component. b While glial areas are reticulin poor, c, mesenchymal component was reticulin rich. d.
Focal bizarre tumor cells in mesenchymal component
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our series and additional mesenchymal differentiation in
the form of bone and cartilage formation was seen in
one case. Similarly, adenoid (epithelial) differentiation
may be seen in gliosarcoma in all age groups and such
areas may resemble carcinoma resulting in misdiagnosis.
Squamous metaplasia may be seen and can be mistaken
for squamous cell carcinoma. The presence of gemisto-
cytic and rhabdoid cells may lead to erroneous diagnosis
of gemistocytic astrocytoma and atypical teratoid/rhab-
doid tumor in the pediatric age group. Gemistocytic and
rhabdoid cells were seen in one and two cases respect-
ively in our series. In pediatric patients, germ cell tumors
(such as germinoma and teratoma) should also be con-
sidered in the differential diagnosis. Gliosarcoma in
pediatric patients can especially be confused with tera-
toma if bone, cartilage or other mesenchymal compo-
nents are present [22, 39–43]. Desmoplastic infantile
astrocytoma (DIA) is another rare tumor which can be
confused with gliosarcoma in the pediatric age group.
However, DIA is a slow growing, WHO grade I tumor
which typically occurs in infants as a large cystic mass in
the supratentorial cerebral cortex and meninges and
is often attached to the dura. Microscopically, it is
composed of a prominent desmoplastic stroma in
which streams of neoplastic astrocytes are seen. Mi-
totic activity and necrosis are uncommon and ki67
index is usually < 2% [1].
At the molecular level, gliosarcomas including those
in the pediatric age group demonstrate Phosphatase
and Tensin homolog (PTEN) and TP53 mutations
and Cyclin-dependent kinase inhibitor 2A (CDKN2A)
deletions. Epidermal growth factor receptor (EGFR)
amplification is infrequent. Except for the last, their
genetic profile is similar to that of IDH-wild type
glioblastoma. Gains on chromosome 7 are seen in
75% cases while losses on chromosome 10 are seen in
35% [44]. In a study of adult gliosarcomas by Smith
et al., these tumors were primarily 0–6-Methylgua-
nine-DNA-Methyltransferase (MGMT) unmethylated
(87.5%), IDH-1 preserved (100%) and EGFR wild type
(100%). A 2019 study by Lowder et al. demonstrated
that the most frequent alteration was copy number
loss comprising 57% of total copy number changes
and far exceeding the number of copy number gains
(26.2%), amplifications and loss of heterozygosity
events. Chromosomes 9 and 10 showed the highest
number of losses while the majority of copy number
gains were seen on chromosome 7 [45, 46]. Recently,
Graham et al. reported a gliosarcoma in an eleven-
year-old girl and a twelve-year-old boy. The latter
had neurofibromatosis type 1 (NF1), the first reported
case of pediatric gliosarcoma in a child with NF1.
Whole-exome sequencing showed higher mutational
burden in the patient without NF. NF1 patient sur-
vived without progression while patient without NF1
died of disease [36].
Occasional case reports documenting pediatric gliosar-
comas in locations other than the cerebral hemispheres
have been published. Neelima et al. reported a case oc-
curring in the thalamus [21]. A case of pediatric gliosar-
coma associated with NF1 was recently reported by
Dogan et al. [33]. Granados et al. reported a pineal glio-
sarcoma in a five-year-old girl, the first reported case in
this unusual location [29].
Fig. 4 a. Trabeculae of lamellar bone in mesenchymal component. b. Prominent large vessels were noted in some cases. c & d Sheets of
gemistocytes and rhabdoid cells are focally seen in few cases
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Various studies have emphasized the importance of
gross total resection in achieving relatively better
prognosis [23, 32]. Studies have shown that subtotal
resection is the most important variable in the dismal
prognosis associated with pediatric gliosarcomas in
most cases [31]. However, a number of studies have
shown that prognosis is dismal even in cases where
apparent gross total resection was achieved and in
spite of aggressive chemo and radiotherapy post re-
section [15, 20, 26], median overall survival and event
free survival have been only a few months, mostly
under a year [15, 20, 37]. Few studies, however, have
reported better prognosis and long-term survival with
aggressive treatment (gross total resection, chemother-
apy and radiotherapy [18, 24, 47]. However, overall,
pediatric gliosarcomas share a dismal prognosis with
adult gliosarcoma. Thus, although a longer survival
has been reported in a few cases, the majority of pa-
tients demonstrate an extremely poor prognosis with
early recurrence and death within a few months after
surgery even after apparent gross total resection and
aggressive post-surgical chemo and radiotherapy [26,
31]. This was true for our cases except for two pa-
tients who survived for 14 months and 2 years re-
spectively post resection. Both these patients received
chemo and radiotherapy. Findings of comprehensive
literature review are summarized in Table 2.
Mallick et al. published a series of five cases of
pediatric gliosarcoma and investigated the value of con-
current and adjuvant temozolamide in the treatment of
these tumors. They showed that temozolamide is well
tolerated by pediatric patients and survival data with
temozolamide therapy was encouraging. The two-year
progression free and overall survival rates were 44.2 and
62.9%, respectively [27].
Limitations
1) Follow up was available in only 9 out of 11 cases
2) Molecular workup was not performed.
Conclusions
Pediatric gliosarcomas are extremely rare. Clinicopatho-
logical features of pediatric gliosarcoma are similar to
adult gliosarcoma. However, pediatric gliosarcomas may
mimic more common tumors on radiological and histo-
logical examination. On histological examination, glio-
sarcomas may sometimes mimic sarcoma and carcinoma
if specific mesenchymal and glandular differentiation is
present. In pediatric age group, osteosarcoma, fibrosar-
coma, teratoma, and atypical teratoid/rhabdoid tumor
should be excluded. Like their adult counterparts,
pediatric gliosarcomas have a dismal prognosis in spite
of aggressive chemoradiation. Slightly better survival
times have been demonstrated in some studies with
gross total resection although other studies have shown
extremely poor survival even with apparent gross total
resection.
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